News

Go Zebra Striped on Social Media This November

To Help Raise Awareness of NETs and Carcinoid Cancer,
The Carcinoid Cancer Foundation Is Making It Possible
To Add Zebra Stripes to Your Facebook Photo

In anticipation of Worldwide NET Cancer Awareness Day on November 10 and throughout the month of November,…

Join Our Twitter Chat on NET Cancer Day

The Carcinoid Cancer Foundation is hosting “Conquering NETs/Carcinoid Cancer Misdiagnoses” Twitter Chat with Steven K. Libutti, MD on November 10, 2015

To help bring attention to NETs/carcinoid cancer, we invite you to join the Carcinoid…

Peptide Receptor Radiotherapy for Neuroendocrine Tumors — Free Webinar on October 20, 2015

Learn more about Peptide Receptor Radionuclide Therapy (PRRT), how it works, where it is being used, and who is eligible for this treatment. Join Josh Mailman, President of NorCal CarciNET; Dr. Edward M. Wolin, Director of Neuroendocrine and GI Oncology…

“The Waiting Room,” a Lung Carcinoid Survivor’s Story

“We are survivors here, in the waiting room.” Lisa Pawlak, a lung carcinoid survivor, shares her inspiring story in the September/October 2015 issue of Coping with Cancer Magazine.  Read Lisa’s article here.…

Smart Patients Carcinoid and Neuroendocrine Tumor Community — Join the Conversation!

The Carcinoid Cancer Foundation is excited to announce a new online community for carcinoid and neuroendocrine tumor (NET) patients, their families and friends. We are partnering with Smart Patients to build this community and hope that combining …

September Luncheon with the Experts in NYC for Carcinoid and Neuroendocrine Tumor Patients

Carcinoid and neuroendocrine tumor (NET) patients are invited to join three medical experts for Lunch with the Experts in New York City on Sunday, September 27, 2015 at 12:30 pm. This special program was initiated and is sponsored by the Big Apple NETs …

Help Us to Help You: New Survey for the Carcinoid and Neuroendocrine Tumor Community

The Carcinoid Cancer Foundation is always looking at ways of improving content and services available to people living with carcinoid cancer and other neuroendocrine tumors and we are working with a pharmaceutical partner,Ipsen, to better understand…

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…

Educational Program for Oncology Nurses on Emerging Therapies for Neuroendocrine Tumors

“Emerging Therapies for Neuroendocrine Tumors: New Perspectives for Oncology Nurses,” is an educational program jointly provided by the Postgraduate Institute for Medicine and the Center of Excellence Media, LLC. The program, offered through June…

Call for Nominations: 6th Annual Warner Advocacy Award

Do you know someone who is a passionate advocate for patients with neuroendocrine tumors (NETs)? Novartis Oncology and The NET Alliance are searching for an outstanding NET patient advocate to recognize and honor with the 6th Annual Warner Advocacy …